Blood-clotting illness PVT 30x more prevalent in Moderna, Pfizer Covid-19 recipients than AstraZeneca – Oxford researchers

Sharing is Caring!
A potentially fatal blood-clotting disease is 30 times more common among people who have received the Covid-19 vaccines produced by Moderna and Pfizer than those given the troubled AstraZeneca jab, researchers have found.

A team of scientists from the University of Oxford has found that after vaccination, Vaxzevria (formerly AstraZeneca Covid-19 vaccine) recipients were less likely to suffer portal vein thrombosis (PVT) – blood clots in the artery from the intestines to the liver.

See also  Pfizer CEO Warns New Vaccine To Combat Heavily-Mutated Coronavirus Could Take 100 Days

For recipients of the viral vector Vaxzevria vaccine, the incidence rate for splanchnic thrombosis – clotting in the portal and other abdominal veins – is 1.6 per million people, according to data from the EU drugs regulator the European Medicines Agency (EMA). By contrast, some 44.9 cases of PVT per million people were seen among those who had been injected with the mRNA vaccines made by Moderna and Pfizer, the Oxford research, published on Thursday, said.

See also  New Botswana variant with 32 'horrific' mutations is the most evolved Covid strain EVER

 

www.rt.com/news/521313-pvt-bloodclot-mrna-covid-vaccines/

1,317 views

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.